Fulcrum Therapeutics, Inc. (FULC)
NASDAQ: FULC · Real-Time Price · USD
4.840
+0.290 (6.37%)
At close: Dec 26, 2024, 4:00 PM
4.770
-0.070 (-1.45%)
After-hours: Dec 26, 2024, 7:05 PM EST
Fulcrum Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
| Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
| Revenue | 80.87 | 2.81 | 6.34 | 19.16 | 8.82 | - | |
| Revenue Growth (YoY) | 2987.86% | -55.77% | -66.90% | 117.19% | - | - | |
| Cost of Revenue | 70.67 | 71.8 | 76.78 | 69.7 | 59.04 | 71.07 | |
| Gross Profit | 10.2 | -69 | -70.44 | -50.54 | -50.22 | -71.07 | |
| Selling, General & Admin | 38.6 | 41.67 | 41.69 | 30.52 | 21.39 | 13.15 | |
| Operating Expenses | 38.6 | 41.67 | 41.69 | 30.52 | 21.39 | 13.15 | |
| Operating Income | -28.4 | -110.66 | -112.13 | -81.05 | -71.61 | -84.22 | |
| Interest & Investment Income | 12.55 | 13.33 | 2.69 | 0.21 | 0.79 | 1.54 | |
| EBT Excluding Unusual Items | -15.85 | -97.34 | -109.44 | -80.85 | -70.82 | -82.68 | |
| Merger & Restructuring Charges | -2.06 | - | -0.43 | - | - | - | |
| Pretax Income | -17.91 | -97.34 | -109.87 | -80.85 | -70.82 | -82.68 | |
| Net Income | -17.91 | -97.34 | -109.87 | -80.85 | -70.82 | -82.68 | |
| Preferred Dividends & Other Adjustments | - | - | - | - | - | 7.13 | |
| Net Income to Common | -17.91 | -97.34 | -109.87 | -80.85 | -70.82 | -89.81 | |
| Shares Outstanding (Basic) | 62 | 61 | 45 | 35 | 25 | 11 | |
| Shares Outstanding (Diluted) | 62 | 61 | 45 | 35 | 25 | 11 | |
| Shares Change (YoY) | 5.50% | 36.27% | 27.23% | 39.47% | 129.53% | 778.76% | |
| EPS (Basic) | -0.29 | -1.59 | -2.44 | -2.29 | -2.79 | -8.13 | |
| EPS (Diluted) | -0.29 | -1.59 | -2.44 | -2.29 | -2.79 | -8.13 | |
| Free Cash Flow | -8.74 | -91.47 | -99.01 | -80.19 | -55 | -40.43 | |
| Free Cash Flow Per Share | -0.14 | -1.49 | -2.20 | -2.27 | -2.17 | -3.66 | |
| Gross Margin | 12.61% | - | - | -263.73% | - | - | |
| Operating Margin | -35.11% | -3945.24% | -1768.12% | -422.97% | -811.64% | - | |
| Profit Margin | -22.15% | -3470.05% | -1732.43% | -421.89% | -802.66% | - | |
| Free Cash Flow Margin | -10.81% | -3261.07% | -1561.23% | -418.47% | -623.34% | - | |
| EBITDA | -26.67 | -108.49 | -109.72 | -78.54 | -69.23 | -82.16 | |
| D&A For EBITDA | 1.73 | 2.17 | 2.41 | 2.52 | 2.38 | 2.05 | |
| EBIT | -28.4 | -110.66 | -112.13 | -81.05 | -71.61 | -84.22 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.